Trading participation for access to healthcare: the COMPAS trial

This short paper is an open-peer commentary (OPC) to Dave Wendler‘s new justification of paediatric research without therapeutic benefits. Synflorix packshotWendler argues that pediatric clinical research that offers no therapeutic benefits to the participants can be justified on the basis that participating in clinical research qualifies as contributing to a valuable project. Matteo Mameli and I disagree and argue that Wendler’s argument is unsatisfactory in that it fails to consider the context of clinical research, i.e. the conditions in which participants find themselves and, more specifically, the kind of access to health care that they have. In our OPC we provide a concrete example to our arguments, by focusing on the recent COMPAS-Synflorix trial (Argentina, 2008).

Camporesi S, Mameli M. (2012) The context of clinical research and its ethical relevance: The COMPAS trial as a case studyAm Journal Bioethics, 12(1):39-40.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s